In focus · trending topic

levodopa-induced dyskinesia

23 stories · following the connections

Adamas Reports Recent Achievements and Second Quarter 2017 Financial Results

By Nasdaq OMXAug 8, 2017, 8:01 PM UTC

Adamas to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 8, 2017

By Nasdaq OMXAug 1, 2017, 6:33 PM UTC

Adamas Appoints New Chief Financial Officer

By Nasdaq OMXJun 28, 2017, 1:01 PM UTC

Adamas Announces Publication of ADS-5102 Phase 3 EASE LID Clinical Trial in JAMA Neurology

By Nasdaq OMXJun 12, 2017, 8:01 PM UTC

Adamas Presents Expanded Analysis from the ADS-5102 Open-Label Study Showing Tolerability and Durability out to 88 Weeks

By Nasdaq OMXJun 8, 2017, 8:10 PM UTC

Adamas Signs $100 Million Royalty-Backed Note Agreement with HealthCare Royalty Partners

By Nasdaq OMXMay 11, 2017, 1:12 PM UTC

Adamas Reports Recent Achievements and First Quarter 2017 Financial Results

By Nasdaq OMXMay 9, 2017, 8:04 PM UTC

Adamas Reports Recent Achievements and First Quarter 2017 Financial Results

By Nasdaq OMXMay 9, 2017, 8:04 PM UTC